A client with diabetes asks which test shows how well their blood glucose has been controlled over the past few months. Which test should the nurse identify?

The glycosylated hemoglobin assay measures the cumulative non-enzymatic attachment of glucose molecules to circulating red blood cells. Because erythrocytes have a structural lifespan of approximately 120 days, this test provides a reliable, weighted index of long-term glycemic trends. It circumvents short-term daily fluctuations caused by recent diet, exercise, or acute physiological stress. A. HbA1c: This biomarker tracks the stable percentage of glycated hemoglobin, reflecting average plasma glucose concentrations over the preceding 2 to 3 months. It represents the gold-standard diagnostic and monitoring tool for evaluating long-term glycemic control. It directly answers the patient's inquiry about past months. B. Sodium: Serum sodium is an extracellular electrolyte that fluctuates based on fluid volume status, antidiuretic hormone activity, and renal water handling. It does not possess any chemical relationship with glucose levels or carbohydrate metabolism. It cannot evaluate historical glycemic trends. C. Potassium: Intracellular potassium levels shift with acid-base imbalances, renal filtration capacity, and insulin action during acute crises like ketoacidosis. It serves as a marker for neuromuscular and cardiac electrical stability rather than cumulative glucose tracking. It provides no information on long-term sugar trends. D. CBC: A complete blood count measures hematological parameters including erythrocytes, leukocytes, and platelets to evaluate for anemia or infectious processes. While red cell life cycles affect glycation assays, the count itself does not measure circulating glucose or metabolic control. It lacks metabolic tracking capability.